If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||||||||||||
![]() Fundamental & Clinical PharmacologyVolume 19 Issue 1, Pages 1 - 16 Published Online: 20 Jan 2005 Journal compilation © 2010 Société Française de Pharmacologie et de Thérapeutique Published on behalf of the Société Française de Pharmacologie et de Thérapeutique
Abstract | References | Full Text: HTML, PDF (Size: 135K) | Related Articles | Citation Tracking REVIEW ARTICLE Herb–drug interactions: an overview of the clinical evidence Copyright 2005 Blackwell Publishing KEYWORDS complementary medicine • cytochrome P450 • herb–drug interaction • herbal medicine • P-glycoprotein • phytotherapy • St John's wort • warfarin Abstract
Herbal medicines are mixtures of more than one active ingredient. The multitude of pharmacologically active compounds obviously increases the likelihood of interactions taking place. Hence, the likelihood of herb–drug interactions is theoretically higher than drug–drug interactions, if only because synthetic drugs usually contain single chemical entities. Case reports and clinical studies have highlighted the existence of a number of clinically important interactions, although cause-and-effect relationships have not always been established. Herbs and drugs may interact either pharmacokinetically or pharmacodynamically. Through induction of cytochrome P450 enzymes and/or P-glycoprotein, some herbal products (e.g. St John's wort) have been shown to lower the plasma concentration (and/or the pharmacological effect) of a number of conventional drugs, including cyclosporine, indinavir, irinotecan, nevirapine, oral contraceptives and digoxin. The majority of such interactions involves medicines that require regular monitoring of blood levels. To date there is less evidence relating to the pharmacodynamic interaction. However, for many of the interactions discussed here, the understanding of the mechanisms involved is incomplete. Taking herbal agents may represent a potential risk to patients under conventional pharmacotherapy. Received 3 June 2004; revised 26 August 2004; accepted 21 September 2004 |
|
| ||||||||||||||||